Praxis Precision Medicines Business Summary

Praxis Precision Medicines, Inc. (PRAX) is a clinical-stage biopharmaceutical company transitioning into a commercial-stage organization focused on genetic-driven therapies for central nervous system (CNS) disorders. The company generates revenue primarily through strategic collaboration agreements, such as its licensing partnership with UCB and Tenacia Biotechnology, as well as milestone payments and interest on its substantial cash reserves, which reached approximately $1.5 billion in pro forma liquidity as of early 2026. Its business is segmented into two primary therapeutic areas: movement disorders, led by the Phase 3 candidate ulixacaltamide for essential tremor, and epilepsy, featuring a robust pipeline including relutrigine for rare pediatric encephalopathies and vormatrigine for focal onset seizures. Praxis competes directly with established CNS players like Xenon Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, and Sage Therapeutics, positioning itself as a precision-medicine disruptor that leverages its proprietary Cerebrum™ small molecule and Solidus™ antisense oligonucleotide platforms to target specific neuronal excitation-inhibition imbalances. Leadership is spearheaded by President and CEO Marcio Souza, who previously served as Chief Operating Officer at PTC Therapeutics and held senior roles at Shire and Sanofi. The founding team includes Dr. Steven Petrou, a globally recognized leader in ion channel biology who was promoted to President of Research & Development in January 2026, and Dr. Kiran Reddy, a Venture Partner at Blackstone Life Sciences. The executive suite was further strengthened in 2026 with the promotion of Megan Sniecinski to Chief Operating Officer and the addition of high-profile board members Jeffrey B. Kindler, former Chairman and CEO of Pfizer, and Stuart Arbuckle, former COO of Vertex Pharmaceuticals. The company is backed by a prestigious roster of institutional investors, including Blackstone Life Sciences, Novo Holdings, Eventide Asset Management, and Point72 Asset Management, reflecting strong market confidence in its dual New Drug Application (NDA) submissions for ulixacaltamide and relutrigine planned for mid-February 2026.